Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Globus Medical (GMED)

Globus Medical stockholders approve equity plan amendment and elect three-year directors

Neutral Impact 2 of 5 shareholder Written later

At its June 4, 2025 annual meeting, Globus Medical stockholders approved an amendment to the 2021 Equity Incentive Plan, effective that day, and elected four directors to three-year terms. Stockholders also ratified Deloitte & Touche LLP as auditor for 2025 and approved an advisory say-on-pay vote, and the board will now hold these pay votes every year. The results set the rules for equity awards and governance for shareholders going forward.

Key points

  • Equity plan amendment: 247,350,637 for, 76,025,441 against, 49,758 abstain; effective June 4, 2025
  • Directors elected to three-year terms: David C. Paul, Daniel T. Lemaitre, Leslie V. Norwalk, Ann D. Rhoads
  • Deloitte & Touche LLP ratified for fiscal year ending December 31, 2025, with 329,151,186 votes for and 689,046 against
  • Say-on-pay advisory vote approved with 315,631,443 for; stockholders favored annual votes (322,479,669 for 1 Year), and the board will hold them every year

The filing

CompanyGlobus Medical (GMED)
Form8-K, current report
Filed with the SECJun 5, 2025, 4:45 PM ET
Accession number0001562762-25-000158

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.